James P. Long, PhD
Department of Biostatistics, Division of Division of Discovery Science
About James P. Long
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Biostatistics, Division of Division of Discovery Science, University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct Associate Professor, Department of Statistics, Division of Division of Discovery Science, Rice University, Houston, TX
Associate Professor, Department of Quantitative Sciences, Division of Division of Discovery Science, Graduate School of Biological Sciences, Houston, TX
Experience & Service
Institutional Committee Activities
Associate Member, IRB5, 2019 - Present
Associate Member, DSMB, 2019 - 2022
Senator, Faculty Senate, 2015 - 2018
Honors & Awards
2017 | Korean International Statistics Society Career Development Award, Korean International Statistics Society |
2012 | Citadel Fellowship, Citadel LLC |
Professional Memberships
Grant & Contract Support
Title: | Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC) |
Funding Source: | NIH/NCI |
Role: | Statistician |
Title: | Development of a Novel Tumor-targeting and Penetrating Nanosystem for Breast Cancer Therapy |
Funding Source: | Department of Defense (DOD) |
Role: | Co-PI |
Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
Funding Source: | University of Hawaii Cancer Center Subaward-Subcontract |
Role: | Co-I |
Title: | Delineating germline, tumor and extrinsic factors driving mucosal melanoma risk and response |
Funding Source: | US Department of Defense |
Role: | Co-I |
Title: | Targeting Acquired Resistance in KRAS Driven Cancers |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Deep learning microscope for slide-free and digital histology |
Funding Source: | NIH/NIDCR subaward via William Marsh Rice University |
Role: | Co-I |
Title: | A Phase II Study to evaluate the efficacy and safety of pembrolizumab in combination with mitotane in patients with advanced adrenocortical carcinoma |
Funding Source: | NIH/NCI |
Role: | Statistician |
Title: | IRE-based Rational Combination for Effective PDAC Immunotherapy |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | RA200128: Enhancing Axl-targeted therapy in inflammatory breast cancer |
Funding Source: | US Department of Defense |
Role: | Co-I |
Title: | Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Mechanisms associated with organotropic metastasis |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer |
Funding Source: | NIH/NCI subaward via Indiana University |
Role: | Co-I |
Title: | Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Chemoimmunotherapy for Aggressive Variant Prostate Cancers (AVPC) |
Funding Source: | Department of Defense (DOD) |
Role: | Statistician |
Title: | Precision Optical Guidance for Oral Biopsy Based on Next-Generation Hallmarks of Cancer |
Funding Source: | NIH/NIDCR Subaward Rice University |
Role: | Biostatistician |
Title: | Cancer Center Support Grant (CCSG) - Biostatistics Resource Group (BRG) |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Development of Novel Combinational Therapy with Enzalutamide in AR+ TNBC |
Funding Source: | Breast Cancer Research Foundation |
Role: | Co-I |
Title: | Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Theranostic Heterodimer Eph-Targeting Peptides for Ovarian & Breast Cancer |
Funding Source: | Emerson Collective Cancer Research Fund |
Role: | Co-I |
Title: | Assessing imaging biomarkers for response to combined IRE and anti-PD-1 immunotherapy |
Funding Source: | QIAC (Quantitative Imaging Analysis Core) |
Role: | Co-I |
Title: | Study on the predictability of hormone and chemo resistance in luminal BC patients who have received CDK4/6 inhibitor by Gene Expression Analysis (and analyze TNBC Patients who have FGFR mutations) |
Funding Source: | Eisai Medical Research subaward via Showa University |
Role: | Collaborator |
Title: | Safety and Efficacy of Therapeutic Exosomes in Models of Glioblastoma Multiforme and Leptomeningeal Disease |
Funding Source: | Codiak Biosciences |
Role: | Biostatistician |
Title: | Development of novel therapy by targeting tumor microenvironment in inflammatory breast cancer |
Funding Source: | Breast Cancer Research Foundation |
Role: | Co-I |
Title: | Quantitative Imaging Biomarkers of Immune Response in Melanoma Brain Metastases |
Funding Source: | MD Anderson – APOLLO Moon Shot Platform |
Role: | Co-Investigator/Collaborator |
Title: | 99mTc/Re Biguanide Complexes Targeting Mitochondria for Pancreatic Cancer Theranostics |
Funding Source: | CABI Pilot Project Program (CP3) |
Role: | Collaborator |
Title: | Enhancing EGFR-targeted therapy by blocking immunosuppression in the tumor microenvironment in inflammatory breast cancer |
Funding Source: | Emerson Collective |
Role: | Collaborator |
Title: | SPORE in Brain Cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Center for Clinical and Translational Science |
Funding Source: | NIH/NCATS subaward via UT Health Science Center, Houston |
Role: | Collaborator |
Title: | Rigorous and reproducible mutational analysis of the urinary exosomal DNA |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Development of Novel Combinational Therapy with Enzalutamide in AR+ TNBC |
Funding Source: | Breast Cancer Research Foundation |
Role: | Co-I |
Title: | Chemoprevention of Hepatocellular Carcinoma by Disrupting Crosstalk Between c-Myc-expressing Hepatocytes and Hepatic Stellate Cells |
Funding Source: | Duncan Family Institute for Cancer Prevention and Risk Assessment Seed-funding Research Program |
Role: | Collaborator |
Title: | The Transformative Glioblastoma Initiative |
Funding Source: | Brockman Foundation |
Role: | Co-I |
Title: | Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and Cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Mapping Milky Way Halo Structures using Variable Stars in the Dark Energy Survey |
Funding Source: | Texas A&M |
Role: | Co-PI |
Title: | MD Anderson Cancer Center Prostate Cancer SPORE. Core 1: Biostatistics Core |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Acute Myeloid Leukemia in the Immunosuppressed |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Biostatistician |
Title: | A Clinical Validation Center for Early Detection of Pancreatic Cancer |
Funding Source: | NIH/NCI |
Role: | Statistician |
Title: | The CANDELS Lyman-alpha Emission At Reionization (CLEAR) Experiment (STSI Cycle 23 Phase 2) |
Funding Source: | NASA |
Role: | Co-I |
Title: | MD Anderson Cancer Center Prostate Cancer SPORE Core 1: Biostatistics and Bioinformatics |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | PTDSS1 as a Novel Target to Improve Anti-tumor Immune Responses with Immune Checkpoint Therapy |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | The Stereotactic Radiologic-Pathologic Imaging Trial: Improving Image-Guided Treatment Planning for Adult Glioma |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Establishing a non-invasive immune checkpoint inhibitor associated nephritis signature |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | In Silico Cell Line Perturbation Response Prediction: New Models and Experimental Validation |
Funding Source: | NIH/NCI |
Role: | PI |
Title: | Electrothermal flow-enhanced biosensor for rapid quantification of acute interstitial nephritis urinary biomarkers |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Rapid urine test for detecting cancer immunotherapy toxicity |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-I |
Title: | Levels and Trajectories of Exosomal MicroRNAs and Proteins Quantified by an Ultrasensitive Nanoplasmonic Biosensor for Early Detection of Pancreatic Cancer |
Funding Source: | NCI (subaward via Indiana University) |
Role: | Co-I |
Title: | Development of an Immune Checkpoint Inhibitor-associated Nephritis Signature |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC) |
Funding Source: | NIH/NCI |
Role: | Statistician |
Title: | PTDSS1 as a novel target to improve anti-tumor immune responses with immune checkpoint therapy |
Funding Source: | NIH/NCI |
Role: | Collaborator |
Title: | Multi-platform Cellular Perturbation Response Prediction using Deep Learning Causal Models with In Vitro Model Validation |
Funding Source: | NIH/NHGRI |
Role: | PD/PI |
Title: | Reduction of Toxicity Using Online Adaptive Radiotherapy for Locally Advanced Cervical Cancer (ROAR C2) FP00018296 |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Development of tumor-specific antibody-drug conjugates for breast cancer |
Funding Source: | University of Texas at Austin |
Role: | Co-I |
Title: | The Stereotactic Radiologic-Pathologic Imaging Trial: Improving Image-Guided Treatment Planning for Adult Glioma |
Funding Source: | NIH/NCI |
Role: | Statistician |
Title: | Rapid urinary test for detecting cancer immunotherapy toxicity |
Funding Source: | Subaward via William Marsh Rice University |
Role: | Biostatistician |
Title: | High Dimensional Causal Discovery for Cellular Perturbation Response Prediction with Application to LINCS L1000 |
Funding Source: | NIH/NHGRI |
Role: | PD/PI |
Title: | Radiotheranostic Heterodimeric Peptides Targeting EphB4/EphA2 in HGSOC with Adaptive Resistance to Anti-VEGF Therapy |
Funding Source: | US Department of Defense |
Role: | Co-I |
Title: | Developing a novel combination immunotherapy for triple‐negative breast cancer/ BC220380 |
Funding Source: | Department of Defense (DOD) |
Role: | Co-I |
Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Investigation of functional connection between pulmonary fibrosis and lung cancer |
Funding Source: | NIH/NHLBI |
Role: | Collaborator |
Title: | MD Anderson Cancer Center Prostate Cancer SPORE |
Funding Source: | NIH/NCI |
Role: | Core 1 Co-Investigator |
Title: | MD Anderson Cancer Center Prostate Cancer SPORE |
Funding Source: | NIH/NCI |
Role: | Core 1 Co-Investigator |
Title: | LC210324 Blood based biomarkers as a complement to CT screening for lung cancer |
Funding Source: | US Department of Defense |
Role: | Co-I |
Title: | Unraveling the functional contribution of extracellular vesicles in pancreatic cancer |
Funding Source: | NIH-DIVISION OF INTRAMURAL RESEARCH |
Role: | Collaborator |
Title: | Exploiting Apoptosis to Induce Immunogenic Cell Death |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | Point-of-care test for patient self-monitoring during cancer immunotherapy |
Funding Source: | William Marsh Rice University |
Role: | Biostatistician |
Title: | Quantitative Imaging Data Quality Grading System for Robust Training and Deployment of Deep-Learning Algorithms in Cancer |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Enhancing Antitumor Immunity with Nanoparticle-mediated Photothermolysis |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Estimation of Aggressive Disease to Guide Surgical Resection In Glioma Patients |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | The Stereotactic Radiology-Pathology Trial II: Prospective Imaging-Pathologic Correlation in Glioma |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Blood based biomarkers to complement and expand low-dose CT screening for lung cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Multimodal Optical Imaging to Improve Real-Time Margin Assessment During Oral Cancer Surgery |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | Development of novel tumor microenvironment targeted therapy in inflammatory breast cancer |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | Blood based biomarkers to complement and expand low-dose CT screening for lung cancer |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | A composite biomarker and radiomic score for risk stratification of indeterminate pulmonary nodules |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | BC210626: Development of novel tumor microenvironment targeted therapy in inflammatory breast cancer |
Funding Source: | US Department of Defense |
Role: | Co-I |
Title: | LC200363 Blood-based biomarkers as a complement to CT screening for lung cancer |
Funding Source: | US Department of Defense |
Role: | Co-I |
Title: | South Texas Center for Chronic Disease Associated with Health Disparities in Mexican Americans |
Funding Source: | Subaward-Subcontract from University of Texas Rio Grange Valley School of Medicine |
Role: | Biostatistician |
Title: | Enhancing Antitumor Immunity with Nanoparticle-mediated Photothermolysis against Hepatocellular Carcinoma |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Potentiation of Anti-Angiogenic Therapy by Inhibitors of Energy Metabolism |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Enhancing Antitumor Immunity with Nanoparticle-mediated Photothermolysis |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Quantitative Imaging Data Quality Grading System for Robust Training and Deployment of Deep-Learning Algorithms in Cancer |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Modulation of Microglia and T Cell Interactions in Malignant Glioma |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | AI-Enabled WHO Grade Estimation to Guide Accurate Biopsy in Gliomas |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Reversing glioblastoma immunosuppression by aptamer targeting of therapeutic siRNAs |
Funding Source: | NIH/NINDS |
Role: | Biostatistician |
Title: | Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Extracellular Vesicle based Liquid Biopsy for Monitoring Therapy Response in Pancreatic Cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Defining lineage plasticity in androgen-indifferent prostate cancer |
Funding Source: | The Mike Slive Foundation |
Role: | Statistics Expert |
Title: | Manipulating the Microenvironment in a Murine Glioma Model |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | BC200327: Development of a novel JNK-targeted therapy to enhance immunotherapy efficacy in triple-negative breast cancer |
Funding Source: | US Department of Defense |
Role: | Co-I |
Title: | Stereotactic Ablative Radiotherapy for Refractory Lethal Structural Arrhythmias (SABR-Heart) |
Funding Source: | Patient Centered Outcomes Res Inst PCORI |
Role: | Biostatistician |
Title: | Myeloid-mediated mechanisms underlying de novo and acquired resistance against immune checkpoint blockade therapies for triple-negative breast cancer |
Funding Source: | John S Dunn Research Foundation |
Role: | Co-I |
Title: | A Machine Learning Solution for Estimating the Proliferative Marker Ki-67 in Gliomas to Guide Accurate Biopsy, Surgical Planning and Radiation Planning |
Funding Source: | InformAl |
Role: | Co-I |
Title: | JNKs Regulation of Metastatic Tumor Microenvironment in Triple-Negative Breast Cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Potentiation of Anti-angiogenic Therapy by Inhibitors of Energy Metabolism |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Modulation Of The Glioblastoma Immune Landscape With STING |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Quantitative imaging for risk stratification and early detection of hepatocellular carcinoma |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Biostatistician |
Title: | Re-Programming Cancer Associated Fibroblasts in Pancreatic Cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Modulation of Microglia and T Cell Interactions in Malignant Glioma |
Funding Source: | NIH/NCI |
Role: | Biostatician |
Title: | Application of spatially precise imaging-pathology correlations for improved image guidance of stereotactic biopsy |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Mechanisms associated with organotropic metastasis |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | 99mTc/Re Biguanide Complexes as Imaging Probes and Metabolic Modulators for PDAC Theranostics |
Funding Source: | MD Anderson Institutional Research Grant |
Role: | Collaborator |
Title: | Deconstructing AMPK Activity in Prostate Cancer |
Funding Source: | NIH/NCI |
Role: | Collaborator |
Title: | Imaging Biomarkers of Response to Irreversible Electroporation and Anti-PD-1 |
Funding Source: | Pancreatic Cancer Action |
Role: | Co-I |
Title: | Pharmacological Reprogramming of Cancer-Associated Fibroblasts in PDAC |
Funding Source: | Pancreatic Cancer Action |
Role: | Co-I |
Title: | Evolution of the immune microenvironment as determinants of breast ductal carcinoma in situ progression |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | Chemoprevention of Hepatocellular Carcinoma by Deactivation of Hepatic Stellate Cells |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | Multimodal Optical Imaging to Improve Real-Time Margin Assessment During Oral Cancer Surgery |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Development of Novel Therapy by Targeting Tumor Microenvironment in Inflammatory Breast Cancer |
Funding Source: | Breast Cancer Research Foundation |
Role: | Co-I |
Title: | Evolution of the immune microenvironment as determinants of breast ductal carcinoma in situ progression |
Funding Source: | Department of Defense (DOD) |
Role: | Co-I |
Title: | Integrative Proteomic-based Biomarker Discovery and Validation of Common Salivary Gland Carcinomas |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Anti-PD-1 exerts therapeutic effects against glioblastoma through innate immunity in the CNS |
Funding Source: | NIH/NCI |
Role: | Biostatistician |
Title: | Multi-Modal Imaging System with Automated Image Analysis for Longitudinal Surveillance and Accurate, Timely Risk Assessment of Oral Precancers |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Imaging and Pathology Quantification of Glioma Heterogeneity |
Funding Source: | American Cancer Society (ACS) |
Role: | Co-PI |
Title: | Center of Excellence in Rare Salivary Gland Cancers |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Assessing Imaging Biomarkers for Response to Combined IRE and Anti-PD-1 Immunotherapy |
Funding Source: | MDACC Sister Institution Network Fund |
Role: | Collaborator |
Title: | Levels and Trajectories of Exosomal MicroRNAs and Proteins Quantified by an Ultrasensitive Nanoplasmonic Biosensor for Early Detection of Pancreatic Cancer |
Funding Source: | INDIANA UNIVERSITY |
Role: | PD/PI |
Title: | The Stereotactic Radiologic-Pathologic Imaging Trial: Improving Image-Guided Treatment Planning for Adult Glioma |
Funding Source: | NATIONAL INSTITUTES OF HEALTH |
Role: | Co-I |
Title: | In Silico Cell Line Perturbation Response Prediction: New Models and Experimental Validation |
Funding Source: | NATIONAL INSTITUTES OF HEALTH |
Role: | PD/PI |
Title: | Enabling Differential Expression Analysis with In Silico Perturbation Models: New Methodology and Rigorous Testing |
Funding Source: | NATIONAL INSTITUTES OF HEALTH |
Role: | PD/PI |
Title: | Human Mesenchymal Stem Cells Loaded with a Tumor Selective Oncolytic Adenovirus Administered via Intra-Arterial Injection in Patients with Recurrent High Grade Gliomas |
Funding Source: | NATIONAL INSTITUTES OF HEALTH |
Role: | Co-I |
Title: | Leveraging Prostate Cancer’s Unique Lipid Metabolism to Induce Therapeutic Ferroptosis |
Funding Source: | US Department of Defense |
Role: | Statistician |
Title: | RP250154: Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients |
Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
Role: | Biostatistician |
Title: | Imaging and Genomic biomarkers for detection of MASLD-related HCC |
Funding Source: | NATIONAL INSTITUTES OF HEALTH |
Role: | Biostatistician |
Title: | A Novel Tumor-Targeting and Penetrating Nanoparticle for Simultaneous Delivery of Multiple Therapeutics for Advanced Ovarian Cancer |
Funding Source: | EnduRX Pharmaceuticals, Inc |
Role: | Co-I |
Title: | Histone lactylation(s) orchestrate epigenetic and transcriptional networks driving CD8 T cell metabolism and function |
Funding Source: | NATIONAL INSTITUTES OF HEALTH |
Role: | Co-I |
Title: | SPORE in Brain Cancer |
Funding Source: | NIH/NCI |
Role: | Co-Director |
Title: | Center for Clinical and Translational Science - UM1 |
Funding Source: | University of Tx Health Science Center - Houston |
Role: | BERD co-investigator |
Title: | Exosomes and MicroRNA in Glioma Therapy |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | The Role of CDKN2A inactivation as a mediator of immunosuppression in pancreatic cancer |
Funding Source: | CONQUER CANCER FOUNDATION |
Role: | Co-I |
Title: | BC190193P1 Development of a Novel Tumor-targeting and Penetrating Nanosystem for Breast Cancer Therapy |
Funding Source: | US Department of Defense |
Role: | PD/PI |
Title: | Enhancing Axl-targeted therapy in inflammatory breast cancer |
Funding Source: | University of Hawaii Cancer Center Subaward-Subcontract |
Role: | Co-I |
Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
Funding Source: | University of Hawaii Cancer Center |
Role: | Co-I |
Title: | Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer |
Funding Source: | NIH/NCI, Subaward VIA University of Hawaii Cancer Center |
Role: | Co-I |
Patient Reviews
CV information above last modified October 10, 2024